Search - tctmd.com

Displaying 161 - 180 of 2580

Sort: Relevancy | Date

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease I. TAVR in Patients With Mitral Regurgitation - Outcomes and Management Strategies (Including MitraClip)

Presenter: A. Pieter Kappetein, Allan Schwartz, Marco Barbanti

October 30, 2016

Presentation TCT 2016

Symptomatic High-Risk Aortic Regurgitation: Is TAVR A Viable Alternative?

Presenter: A. Pieter Kappetein, Allan Schwartz, Hendrik Treede

October 30, 2016

Presentation TCT 2016

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

Presenter: A. Pieter Kappetein, Allan Schwartz, Martin B. Leon

October 30, 2016

Presentation TCT 2016

Low-Flow Aortic Stenosis: Clinical Outcomes After TAVR

Presenter: A. Pieter Kappetein, Allan Schwartz, Howard C. Herrmann

October 30, 2016

Presentation TCT 2016

Low-Flow Aortic Stenosis: Pathophysiology, Syndrome Classification, and Prognosis

Presenter: A. Pieter Kappetein, Allan Schwartz, Philippe Pibarot

October 30, 2016

Presentation TCT 2016

Transcatheter Valve-in-Valve Therapy: Clinical and Technical Pearls

Presenter: A. Pieter Kappetein, Allan Schwartz, Vinayak Bapat

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Presenter: Charles J. Davidson, Nicole Ibrahim, Paul Sorajja

October 30, 2016

Presentation TCT 2016

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

Presenter: A. Pieter Kappetein, Allan Schwartz, Danny Dvir

October 30, 2016

Presentation TCT 2016

TAVR Outcomes and Technical Pearls in Bicuspid Aortic Stenosis (With Case Examples)

Presenter: A. Pieter Kappetein, Allan Schwartz, Mathew Williams

October 30, 2016

Presentation TCT 2016

Bicuspid Aortic Valve Disease: Epidemiology, Anatomy, Classification, and Special Considerations for TAVR

Presenter: A. Pieter Kappetein, Allan Schwartz, Lars Sondergaard

October 30, 2016

Presentation TCT 2016

Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR!

Presenter: Russell A. Brandwein, Isaac George

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, David J. Cohen

October 30, 2016

Presentation TCT 2016

Debate: TAVR for Low Risk Patients Is It time? YES, the Data Is Sufficient and Our Patients Want It!

Presenter: Russell A. Brandwein, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Simultaneous TAVR and Endovascular Aortic Aneurysm Repair

Presenter: Habib Gamra, Mahmoud Hashemian, Abdullah Shehab, Walid Ouertani

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Lars G. Svensson

October 30, 2016

Presentation TCT 2016

Flash Debate: Point Surgical Risk Stratification for TAVR Should Be Replaced by Anatomic and Clinical Profiling!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Stephan Windecker

October 30, 2016

Presentation TCT 2016

TCT 648: Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement

Presenter: Jean-Claude Laborde, Azfar G. Zaman

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Neil E. Moat

October 30, 2016

Advertisement

Aortic Stenosis + Concomitant Disease I. TAVR in Patients With Mitral Regurgitation - Outcomes and Management Strategies (Including MitraClip)

Symptomatic High-Risk Aortic Regurgitation: Is TAVR A Viable Alternative?

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

Low-Flow Aortic Stenosis: Clinical Outcomes After TAVR

Low-Flow Aortic Stenosis: Pathophysiology, Syndrome Classification, and Prognosis

Transcatheter Valve-in-Valve Therapy: Clinical and Technical Pearls

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

TAVR Outcomes and Technical Pearls in Bicuspid Aortic Stenosis (With Case Examples)

Bicuspid Aortic Valve Disease: Epidemiology, Anatomy, Classification, and Special Considerations for TAVR

Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR!

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Debate: TAVR for Low Risk Patients Is It time? YES, the Data Is Sufficient and Our Patients Want It!

Simultaneous TAVR and Endovascular Aortic Aneurysm Repair

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Flash Debate: Point Surgical Risk Stratification for TAVR Should Be Replaced by Anatomic and Clinical Profiling!

TCT 648: Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content